Brain-derived neurotrophic factor and major depressive disorder: Evidence from meta-analyses

Taro Kishi, Reiji Yoshimura, Toshikazu Ikuta, Nakao Iwata

Research output: Contribution to journalShort survey

24 Citations (Scopus)

Abstract

A ccumulating evidence suggests that brain-derived neurotrophic factor (BDNF) is associated with the pathophysiology of major depressive disorder (MDD). In this mini review, we explored the association between BDNF and MDD using meta-analytic evidence. Our findings indicated that the Val66Met polymorphism in the BDNF gene was not associated with MDD or hippocampal volume in patients with MDD. However, plasma/serum levels of BDNF were decreased in patients with acute MDD compared with healthy controls. Both antidepressant treatment and electroconvulsive therapy increased plasma and serum levels of BDNF in patients with MDD. Val66Met polymorphism in the BDNF gene was associated with an antidepressant response in patients with MDD. Taken together, we did not detect any plausible evidence regarding Val66Met polymorphism in the BDNF gene contributing to a risk of MDD. However, peripheral BDNF levels are decreased in patients with MDD, and the polymorphisms are associated with treatment response. In conclusion, BDNF is best understood to be a biomarker for the state of MDD and its treatment response rather than a risk factor for MDD.

Original languageEnglish
Article number308
JournalFrontiers in Psychiatry
Volume8
Issue numberJAN
DOIs
Publication statusPublished - 17-01-2018

Fingerprint

Brain-Derived Neurotrophic Factor
Major Depressive Disorder
Meta-Analysis
Antidepressive Agents
Genes
Electroconvulsive Therapy
Serum
Therapeutics
Biomarkers

All Science Journal Classification (ASJC) codes

  • Psychiatry and Mental health

Cite this

@article{3155931076754c0fab7437972f769dd7,
title = "Brain-derived neurotrophic factor and major depressive disorder: Evidence from meta-analyses",
abstract = "A ccumulating evidence suggests that brain-derived neurotrophic factor (BDNF) is associated with the pathophysiology of major depressive disorder (MDD). In this mini review, we explored the association between BDNF and MDD using meta-analytic evidence. Our findings indicated that the Val66Met polymorphism in the BDNF gene was not associated with MDD or hippocampal volume in patients with MDD. However, plasma/serum levels of BDNF were decreased in patients with acute MDD compared with healthy controls. Both antidepressant treatment and electroconvulsive therapy increased plasma and serum levels of BDNF in patients with MDD. Val66Met polymorphism in the BDNF gene was associated with an antidepressant response in patients with MDD. Taken together, we did not detect any plausible evidence regarding Val66Met polymorphism in the BDNF gene contributing to a risk of MDD. However, peripheral BDNF levels are decreased in patients with MDD, and the polymorphisms are associated with treatment response. In conclusion, BDNF is best understood to be a biomarker for the state of MDD and its treatment response rather than a risk factor for MDD.",
author = "Taro Kishi and Reiji Yoshimura and Toshikazu Ikuta and Nakao Iwata",
year = "2018",
month = "1",
day = "17",
doi = "10.3389/fpsyt.2017.00308",
language = "English",
volume = "8",
journal = "Frontiers in Psychiatry",
issn = "1664-0640",
publisher = "Frontiers Research Foundation",
number = "JAN",

}

Brain-derived neurotrophic factor and major depressive disorder : Evidence from meta-analyses. / Kishi, Taro; Yoshimura, Reiji; Ikuta, Toshikazu; Iwata, Nakao.

In: Frontiers in Psychiatry, Vol. 8, No. JAN, 308, 17.01.2018.

Research output: Contribution to journalShort survey

TY - JOUR

T1 - Brain-derived neurotrophic factor and major depressive disorder

T2 - Evidence from meta-analyses

AU - Kishi, Taro

AU - Yoshimura, Reiji

AU - Ikuta, Toshikazu

AU - Iwata, Nakao

PY - 2018/1/17

Y1 - 2018/1/17

N2 - A ccumulating evidence suggests that brain-derived neurotrophic factor (BDNF) is associated with the pathophysiology of major depressive disorder (MDD). In this mini review, we explored the association between BDNF and MDD using meta-analytic evidence. Our findings indicated that the Val66Met polymorphism in the BDNF gene was not associated with MDD or hippocampal volume in patients with MDD. However, plasma/serum levels of BDNF were decreased in patients with acute MDD compared with healthy controls. Both antidepressant treatment and electroconvulsive therapy increased plasma and serum levels of BDNF in patients with MDD. Val66Met polymorphism in the BDNF gene was associated with an antidepressant response in patients with MDD. Taken together, we did not detect any plausible evidence regarding Val66Met polymorphism in the BDNF gene contributing to a risk of MDD. However, peripheral BDNF levels are decreased in patients with MDD, and the polymorphisms are associated with treatment response. In conclusion, BDNF is best understood to be a biomarker for the state of MDD and its treatment response rather than a risk factor for MDD.

AB - A ccumulating evidence suggests that brain-derived neurotrophic factor (BDNF) is associated with the pathophysiology of major depressive disorder (MDD). In this mini review, we explored the association between BDNF and MDD using meta-analytic evidence. Our findings indicated that the Val66Met polymorphism in the BDNF gene was not associated with MDD or hippocampal volume in patients with MDD. However, plasma/serum levels of BDNF were decreased in patients with acute MDD compared with healthy controls. Both antidepressant treatment and electroconvulsive therapy increased plasma and serum levels of BDNF in patients with MDD. Val66Met polymorphism in the BDNF gene was associated with an antidepressant response in patients with MDD. Taken together, we did not detect any plausible evidence regarding Val66Met polymorphism in the BDNF gene contributing to a risk of MDD. However, peripheral BDNF levels are decreased in patients with MDD, and the polymorphisms are associated with treatment response. In conclusion, BDNF is best understood to be a biomarker for the state of MDD and its treatment response rather than a risk factor for MDD.

UR - http://www.scopus.com/inward/record.url?scp=85040837405&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040837405&partnerID=8YFLogxK

U2 - 10.3389/fpsyt.2017.00308

DO - 10.3389/fpsyt.2017.00308

M3 - Short survey

AN - SCOPUS:85040837405

VL - 8

JO - Frontiers in Psychiatry

JF - Frontiers in Psychiatry

SN - 1664-0640

IS - JAN

M1 - 308

ER -